National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic evaluation of oral tapentadol (Palexia®) for the management of adult patients with severe chronic/acute pain.

Rapid Review

Commenced Completed Outcome
19/10/2010 22/10/2010 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
31/01/2011 08/04/2011 Reimbursement Recommended

Tapentadol (Palexia®) may be considered cost-effective but should be reserved for patients who cannot tolerate existing strong oral opioids.

Tapentadol (Palexia®) summary